Who is affected by this change?

This affects Independence Blue Cross Oncology, Hematology providers on Commercial plans.

When does this change take effect?

This change is effective Jul 28, 2025.

Back to dashboard

CommercialCoverageMedium impact

08.02.40, Cosibelimab-ipdl (Unloxcyt™)

Independence Blue Cross·Oncology, Hematology·Pharmacy

Effective date

Jul 28, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

A new policy 08.02.40 for Cosibelimab-ipdl (Unloxcyt™) has been established, which is a pharmacy-related coverage policy for this medication. This appears to be establishing initial coverage criteria and billing guidelines for this drug therapy.

Action Required

Action needed

By July 28, 2025: Review the full policy details at the provided URL to understand coverage criteria, prior authorization requirements, and billing guidelines for Cosibelimab-ipdl (Unloxcyt™). Update pharmacy billing procedures and ensure staff are aware of any coverage limitations or documentation requirements for this new drug policy.

Related policy hubs

Independence Blue Cross policies Oncology Hematology